2021
Spatial Analysis and Clinical Significance of HLA Class-I and Class-II Subunit Expression in Non–Small Cell Lung Cancer
Datar IJ, Hauc SC, Desai S, Gianino N, Henick B, Liu Y, Syrigos K, Rimm DL, Kavathas P, Ferrone S, Schalper KA. Spatial Analysis and Clinical Significance of HLA Class-I and Class-II Subunit Expression in Non–Small Cell Lung Cancer. Clinical Cancer Research 2021, 27: 2837-2847. PMID: 33602682, PMCID: PMC8734284, DOI: 10.1158/1078-0432.ccr-20-3655.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerNK cell infiltrationReduced T cellCell lung cancerHLA class IIT cellsLung cancerHLA classClinical significanceSubunit expressionHLA class II downregulationΒ2MClass IIHLA genesHuman leukocyte antigen classShorter overall survivalTumor microenvironment compositionClass II β chainImmune contextureOverall survivalLung malignancyNatural killerPatient survivalCell infiltrationClinicopathologic variables
2020
Biomarkers in Precision Cancer Immunotherapy: Promise and Challenges.
McKean WB, Moser JC, Rimm D, Hu-Lieskovan S. Biomarkers in Precision Cancer Immunotherapy: Promise and Challenges. American Society Of Clinical Oncology Educational Book 2020, 40: e275-e291. PMID: 32453632, DOI: 10.1200/edbk_280571.Peer-Reviewed Original ResearchConceptsHost immune defectsPrecision cancer immunotherapyHealth care burdenCurrent treatment modalitiesSignificant side effectsSustained remissionClinical responseCheckpoint inhibitionImmune defectsRefractory malignanciesCancer immunotherapeuticsClinical benefitPatient survivalCancer immunotherapyPredictive biomarkersTreatment modalitiesCare burdenPatient responseSide effectsTrial designTumor parenchymaClinical useBiomarker developmentBiomarkersMultiple biomarkersCompactness measures of tumor infiltrating lymphocytes in lung adenocarcinoma are associated with overall patient survival and immune scores
Ding R, Prasanna P, Corredor G, Lu C, Velu P, Le K, Leo P, Beig N, Velcheti V, Rimm D, Schalper K, Madabhushi A. Compactness measures of tumor infiltrating lymphocytes in lung adenocarcinoma are associated with overall patient survival and immune scores. 2020, 2. DOI: 10.1117/12.2549588.Peer-Reviewed Original Research
2018
Nuclear shape and orientation features from H&E images predict survival in early-stage estrogen receptor-positive breast cancers
Lu C, Romo-Bucheli D, Wang X, Janowczyk A, Ganesan S, Gilmore H, Rimm D, Madabhushi A. Nuclear shape and orientation features from H&E images predict survival in early-stage estrogen receptor-positive breast cancers. Laboratory Investigation 2018, 98: 1438-1448. PMID: 29959421, PMCID: PMC6214731, DOI: 10.1038/s41374-018-0095-7.Peer-Reviewed Original ResearchConceptsEarly-stage estrogen receptor-positive breast cancerEstrogen receptor-positive breast cancerReceptor-positive breast cancerBreast cancerRank sum testHazard ratioHistomorphometric featuresShort-term overall survivalLymph node negativeTissue microarray cohortPoor survival outcomesUnivariate survival analysisWilcoxon rank sum testAdjuvant chemotherapyMicroarray cohortOverall survivalNode negativeT stageHistology gradePatient survivalSurvival outcomesPathological parametersNuclear gradeOutcome groupPoor survival
2009
High Expression of Mammalian Target of Rapamycin Is Associated with Better Outcome for Patients with Early Stage Lung Adenocarcinoma
Anagnostou VK, Bepler G, Syrigos KN, Tanoue L, Gettinger S, Homer RJ, Boffa D, Detterbeck F, Rimm DL. High Expression of Mammalian Target of Rapamycin Is Associated with Better Outcome for Patients with Early Stage Lung Adenocarcinoma. Clinical Cancer Research 2009, 15: 4157-4164. PMID: 19509151, DOI: 10.1158/1078-0432.ccr-09-0099.Peer-Reviewed Original ResearchConceptsLung cancer patientsMTOR expressionCancer patientsMammalian targetEarly-stage lung adenocarcinomaHigh mTOR expressionIndependent lower riskMedian overall survivalStage IA patientsProtein expressionSubgroup of patientsLung adenocarcinoma patientsStage lung adenocarcinomaMTOR protein expressionRole of mTOROverall survivalPathologic characteristicsPatient survivalValidation cohortAdenocarcinoma groupAdenocarcinoma patientsPrognostic stratificationLung cancerTraining cohortFavorable outcomeAssociation of expression of bcl-2 with outcome in non-small cell lung cancer
Anagnostou V, Lowery F, Syrigos K, Frangia K, Zolota V, Panagopoulos N, Dougenis D, Tanoue L, Detterbeck F, Homer R, Rimm D. Association of expression of bcl-2 with outcome in non-small cell lung cancer. Journal Of Clinical Oncology 2009, 27: e22039-e22039. DOI: 10.1200/jco.2009.27.15_suppl.e22039.Peer-Reviewed Original ResearchLung cancer patientsSquamous cell carcinomaBcl-2 expressionCancer patientsCell carcinomaBcl-2Non-small cell lung cancerYale-New Haven HospitalIndependent lower riskPatras University HospitalMedian overall survivalProtein expressionPotential prognostic parametersSubgroup of patientsCell lung cancerHigh Bcl-2 expressionNew Haven HospitalBcl-2 protein expressionAssociation of expressionBcl-2 protein levelsOverall survivalPatient survivalValidation cohortPathological characteristicsPrognostic parameters
2008
Quantitative Assessment of Tissue Biomarkers and Construction of a Model to Predict Outcome in Breast Cancer Using Multiple Imputation
Emerson JW, Dolled-Filhart M, Harris L, Rimm DL, Tuck DP. Quantitative Assessment of Tissue Biomarkers and Construction of a Model to Predict Outcome in Breast Cancer Using Multiple Imputation. Cancer Informatics 2008, 7: cin.s911. PMID: 19352457, PMCID: PMC2664700, DOI: 10.4137/cin.s911.Peer-Reviewed Original ResearchLymph node statusProtein expression levelsNode statusBreast cancerBaseline clinical modelCohort of patientsLack of tumorTissue microarray studyLarge independent cohortsExpression levelsMultiple imputationPatient survivalTraining cohortTissue biomarkersIndependent cohortClinical modelSelect markersCohortSimilar improvementsBiomarker analysisCancerClinical annotationProtein markersBiomarkersFuture studiesThyroid Transcription Factor 1 Is an Independent Prognostic Factor for Patients With Stage I Lung Adenocarcinoma
Anagnostou VK, Syrigos KN, Bepler G, Homer RJ, Rimm DL. Thyroid Transcription Factor 1 Is an Independent Prognostic Factor for Patients With Stage I Lung Adenocarcinoma. Journal Of Clinical Oncology 2008, 27: 271-278. PMID: 19064983, DOI: 10.1200/jco.2008.17.0043.Peer-Reviewed Original ResearchConceptsThyroid transcription factor-1Stage I lung adenocarcinomaTTF1 expressionTranscription factor 1Lung adenocarcinomaStage IIndependent lower riskMedian overall survivalProtein expressionIndependent prognostic factorPotential prognostic parametersSubgroup of patientsFactor 1Overall survivalPrognostic factorsPatient survivalPrognostic parametersPrognostic stratificationLung cancerFavorable outcomeSitu protein expressionIndependent cohortLower riskPatientsAdenocarcinoma
2003
Subcellular localization of activating transcription factor 2 in melanoma specimens predicts patient survival.
Berger AJ, Kluger HM, Li N, Kielhorn E, Halaban R, Ronai Z, Rimm DL. Subcellular localization of activating transcription factor 2 in melanoma specimens predicts patient survival. Cancer Research 2003, 63: 8103-7. PMID: 14678960.Peer-Reviewed Original ResearchConceptsATF2 expressionTranscription factor 2Melanoma specimensUseful prognostic markerEarly-stage melanomaWeak cytoplasmic stainingStrong nuclear stainingFactor 2Mean followCutaneous specimensLocalized diseaseOverall survivalIndependent predictorsPreclinical findingsClark levelClinicopathological dataPatient survivalPoor outcomePrognostic valueWorse outcomesPrognostic markerPoor survivalPreclinical modelsClinical significanceImmunohistochemical staining